Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Hepatology

Volumn 62, Issue 3, 2015, Pages 784-791

  Iavarone, Massimo ^a   Cabibbo, Giuseppe ^b   Biolato, Marco ^c   Della Corte, Cristina ^a   Maida, Marcello ^b   Barbara, Marco ^b   Basso, Michele ^c   Vavassori, Sara ^a   Craxì, Antonio ^b   Grieco, Antonio ^c   Cammà, Carlo ^b   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ABSCESS; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADVANCED CANCER; AGED; ANEMIA; ANORECTAL ABSCESS; ANORECTAL DISEASE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHOLANGITIS; CHOLECYSTITIS; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG WITHDRAWAL; DUODENUM ULCER; ERYSIPELAS; FATIGUE; FEMALE; FEMUR FRACTURE; FOLLOW UP; HAND FOOT SYNDROME; HEART FAILURE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INTRACARDIAC THROMBOSIS; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MILD HEPATIC IMPAIRMENT; OUTCOME ASSESSMENT; PANCYTOPENIA; PATIENT COUNSELING; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RASH; RECTUM HEMORRHAGE; SEPSIS; SURVIVAL PREDICTION; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR INVASION; UPPER GASTROINTESTINAL BLEEDING; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COHORT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ITALY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; REPRODUCIBILITY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL; TREATMENT WITHDRAWAL;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; ITALY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PATIENT SELECTION; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SURVIVAL ANALYSIS; WITHHOLDING TREATMENT;

EID: 84939653557     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27729     Document Type: Article

References (23)

1. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 2013;58:2023-2031.
6. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al.; SOFIA (SOraFenib Italian Assessment) Study Group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-2263.
7. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012;57:101-107.
8. Cammà C, Cabibbo G, Petta S, Enea M, Iavarone M, Grieco A, et al.; WEF study group, SOFIA study group. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 2013;57:1046-1054.
9. Agenzia Italiana del Farmaco. Registro farmaci oncologici sottoposti a monitoraggio. http://antineoplastici.agenziafarmaco.it/normativa_registro_trast.htm. Accessed January 2014.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
12. EU summary of product characteristics for Nexavar. Berlin, Germany: Bayer Schering Pharma AG; November 2010.
13. Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 2014;61:318-324.
14. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 2014;60:313-318.
15. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-157.
16. Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012;104:1534-1541.
17. Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, et al; Okayama Liver Cancer Group. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol Res 2014;44:296-301.
18. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
19. Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival [press release]. Basel, Switzerland: Novartis; November 7, 2013. Available at: http://www.novartis.com/newsroom/media-releases/en/2013/1721562.shtml. Accessed August 2013.
20. Lilly announces top-line results of phase III hepatocellular carcinoma trial [press release]. Indianapolis, IN: Eli Lilly and Company; June 11, 2014. Available at: http://files.shareholder.com/downloads/LLY/3291466134x0x761362/32cec437-a8bc-4cfd-b19a-619a00af44b3/LLY_News_2014_6_11_Product.pdf. Accessed June 2014.
21. Bolos D, Finn RS. Systemic therapy in HCC: lessons from brivanib. J Hepatol 2014;61:947-950.
22. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
23. Combescure C1, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med 2014;33:2521-2537.